"Reasonable pricing" clause
Executive Summary
National Institutes of Health would be directed to reinstate the "reasonable pricing" clause in Cooperative Research & Development Agreements under an amendment sponsored by Rep. Bernie Sanders (I-Vt.) included in the House version of the HHS appropriations bill. The same amendment passed the House last year but was not included in the conference version of the bill, which directed NIH to develop a report on taxpayer-funded research. In the report, NIH repeated its concern that the "reasonable pricing" clause would discourage firms from licensing federal discoveries (1"The Pink Sheet" Aug. 27, p. 3)
You may also be interested in...
NIH Return-On-Investment Report Will Be Subject Of Senate Hearing This Fall
The Senate Commerce/Science Subcommittee will hold hearings this fall on the return to taxpayers from research funded by the National Institutes of Health.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials